US cost–effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health... by Nipun Atreja, Kasper Johannesen, Rupesh Subash, Carina Bektur, Melissa Hagan, Dionne M Hines, Iulia Dunnett, Ewa Stawowczyk

Cost–effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting... by Rupesh Subash, Thomas Strakosch, Michelle Zhang, Melissa Hagan, Elke Dworatzek, Agnes Kisser, Vasileios Vasilopoulos, Chloe Salter, Carissa Dickerso, Ewa Stawowczyk

Comparative safety and effectiveness of oral anticoagulants in key subgroups of patients with non-valvular atrial fibrillation and at high risk of gastrointestinal bleeding: A coho... by Gregory Y H Lip, Robert Benamouzig, Anne-Céline Martin, Giancarlo Pesce, Gaelle Gusto, Nadia Quignot, Artak Khachatryan, Feng Dai, Fouad Sedjelmaci, Jose Chaves, Rupesh Subash, Ruth Mokgokong

Get full text